| Literature DB >> 32325963 |
Luis Amaro1, Daniela M Correia1,2, Pedro M Martins1, Gabriela Botelho3, Sónia A C Carabineiro4, Clarisse Ribeiro1,5, Senentxu Lanceros-Mendez6,7.
Abstract
Poly(hydroxybutyrate-co-hydroxyvalerate) (Entities:
Keywords: hydrolytic degradation; piezoelectric materials; poly(hydroxybutyrate-co-hydroxyvalerate); tissue engineering
Year: 2020 PMID: 32325963 PMCID: PMC7240521 DOI: 10.3390/polym12040953
Source DB: PubMed Journal: Polymers (Basel) ISSN: 2073-4360 Impact factor: 4.329
Figure 1Schematic representation of the steps involved in the degradation assays.
Figure 2Poly(3-hydroxybutyrate-co-hydroxyvalerate) (PHBV) and PHBV/cobalt ferrite (CFO) films, scaffolds and fibers after 1, 2, 4 and 6 weeks immersion in simulated body fluid (SBF) at 37 °C.
Figure 3Cross-section SEM images of representative samples: PHBV/CFO films (a,b), PHBV fibers (c,d), PHBV/CFO fibers (e,f) and PHBV/CFO scaffolds (g,h), before and after degradation, respectively.
Figure 4FTIR spectra of the different PHBV and PHBV/CFO morphologies before (a) and after (b) 6 weeks of immersion in SBF. DSC thermograms of pristine and PHBV/CFO composites (c) before and (d) after 6 weeks of immersion in SBF, respectively.
Tm, ΔHm and XC of PHBV and PHBV/CFO composite non-degraded [8] and degraded samples. The associated error is ±2%.
| Sample | Tm (°C) | ΔHm (J/g) | XC (%) | |
|---|---|---|---|---|
|
| PHBV | 174 | 82 | 56 |
| PHBV/CFO | 177 | 70 | 48 | |
| PHBV (Degraded) | 173 | 40 | 27 | |
| PHBV/CFO (Degraded) | 173 | 66 | 45 | |
|
| PHBV | 175 | 98 | 67 |
| PHBV/CFO | 177 | 67 | 46 | |
| PHBV (Degraded) | 171 | 49 | 33 | |
| PHBV/CFO (Degraded) | 172 | 66 | 45 | |
|
| PHBV (Degraded) | 176 | 45 | 31 |
| PHBV/CFO (Degraded) | 173 | 37 | 25 |
Figure 5XPS results of non-degraded and degraded PHBV and PHBV/CFO samples with different morphologies: (a–c) C1s scan spectra for films, fibers and scaffolds, respectively and (d) O1s spectra.
Surface chemical composition of non-degraded and degraded PHBV and PHBV/CFO samples.
| Samples | Elemental Composition (%) | |||
|---|---|---|---|---|
| C | O | O/C | ||
|
| PHBV film | 69.4 | 30.6 | 0.44 |
| PHBV/CFO film | 71.9 | 28.1 | 0.39 | |
| PHBV fibers | 70.3 | 29.7 | 0.42 | |
| PHBV/CFO fibers | 69.0 | 31.0 | 0.45 | |
| PHBV scaffolds | 73.2 | 26.8 | 0.37 | |
| PHBV/CFO scaffolds | 73.3 | 26.7 | 0.36 | |
|
| PHBV film | 66.8 | 33.3 | 0.49 |
| PHBV/CFO film | 63.7 | 36.0 | 0.56 | |
| PHBV fibers | 69.3 | 30.7 | 0.44 | |
| PHBV/CFO fibers | 66.5 | 33.4 | 0.50 | |
| PHBV scaffolds | 63.2 | 36.8 | 0.58 | |
| PHBV/CFO scaffolds | 68.3 | 31.7 | 0.46 | |
Figure 6Schematic representation of the PHBV hydrolytic degradation [56].
Figure 7Weight loss relative to the original mass after degradation for 2, 6 and 8 weeks in SBF for (a) PHBV and PHBV/CFO films, (b) fibers and (c) scaffolds.
Figure 8Cytotoxicity assay results of MC3T3-E1 pre-osteoblast cells in contact with the as-prepared extraction media exposed to the different PHBV samples after six weeks of degradation for 72 h (relative metabolic activity was presented as the percentage of the negative control with n = 4 ± Standard Deviation).